Canada's Cipher Pharmaceuticals has received final FDA approval for its cholesterol-lowering drug. This is the first FDA approval for Cipher. Lipofen has been OK'd in three different dosages, which is to be used with diet to lower cholesterol. Cipher says its looking to find a U.S. distributor for the drug.
"CIP-Fenofibrate is one of three late-stage products in our pipeline. With an application for CIP-Isotretinoin under review with the FDA and preparations underway to file the CIP-Tramadol application with the FDA in the first half of 2006, we believe that the approval of CIP-Fenofibrate represents the first of a number of significant milestone events for Cipher," said Larry Andrews, president of Cipher Pharmaceuticals.
- read this release for more information